Table II.
p53 | TAp73 | VASH1 | |||||||
---|---|---|---|---|---|---|---|---|---|
Feature | Negative N=79% (n) | Positive N=27% (n) | P-value | Negative N=62% (n) | Positive N=44% (n) | P-value | Negative N=60% (n) | Positive N=46% (n) | P-value |
Mean (±SD) | 64.8 (9.1) | 61.6 (11.2) | 0.140b | 63.5 (9.6) | 64.0 (10.0) | 0.594b | 65.1 (9.4) | 62.4 (10.3) | 0.161b |
Median age | |||||||||
≤60 | 32.9 (26/79) | 44.4 (12/27) | 37.1 (23/62) | 34.1 (15/44) | 30.0 (18/60) | 43.5 (20/46) | |||
>60 | 67.1 (53/79) | 55.6 (15/27) | 0.281a | 62.9 (39/62) | 65.9 (29/44) | 0.751a | 70.0 (42/60) | 56.5 (26/46) | 0.152a |
Sex | |||||||||
Male | 50.6 (40/79) | 59.3 (16/27) | 51.6 (32/62) | 54.5 (24/44) | 51.7 (31/60) | 54.3 (25/46) | |||
Female | 49.4 (39/79) | 40.7 (11/27) | 0.438a | 48.4 (30/62) | 45.5 (20/44) | 0.766a | 48.3 (29/60) | 45.7 (21/46) | 0.784a |
Smoking | |||||||||
Non-smoker | 53.2 (42/79) | 66.7 (18/27) | 56.5 (35/62) | 56.8 (25/44) | 61.7 (37/60) | 50.0 (23/46) | |||
Smoker | 46.8 (37/79) | 33.3 (9/27) | 0.222a | 43.5 (27/62) | 43.2 (19/44) | 0.970a | 38.3 (23/60) | 50.0 (23/46) | 0.230a |
Histological type | |||||||||
Adenocarcinoma | 35.4 (28/79) | 92.6 (25/27) | 16.1 (10/62) | 97.7 (43/44) | 36.7 (22/60) | 67.4 (31/46) | |||
Paraneoplastic | 64.6 (51/79) | 7.4 (2/27) | <0.001a | 83.9 (52/62) | 2.3 (1/44) | <0.001a | 63.3 (38/60) | 32.6 (15/46) | 0.002a |
Disease stage | |||||||||
I | 0 (0/28) | 4.0 (1/25) | 0.339a | 0 (0/10) | 2.3 (1/43) | 0.431a | 0 (0/22) | 3.2 (1/31) | 0.695a |
I–II | 3.6 (1/28) | 0 (0/25) | 0 (0/10) | 2.3 (1/43) | 0 (0/22) | 3.2 (1/31) | |||
II | 78.6 (22/28) | 72.8 (18/25) | 6.0 (6/10) | 79.1 (34/43) | 81.8 (18/22) | 71.0 (22/31) | |||
II–III | 7.1 (2/28) | 20.0 (5/25) | 2.0 (2/10) | 11.6 (5/43) | 9.1 (2/22) | 16.1 (5/31) | |||
III | 10.7 (3/28) | 4.0 (1/25) | 2.0 (2/10) | 4.7 (2/43) | 9.1 (2/22) | 6.5 (2/31) |
Chi-squared P-value.
Student's t-test P-value. Score ≤3 indicates negative expression; score >3 indicates positive expression; SD, standard deviation; I, well-differentiated adenocarcinoma; II, moderately-differentiated adenocarcinoma; III, poorly-differentiated adenocarcinoma; VASH1, vasohibin-1.